Conference Correspondent

Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

Triplet regimens combining an immunomodulatory agent, a proteasome inhibitor, and a steroid are often used to treat newly diagnosed and relapsed multiple myeloma (MM). Lenalidomide (LEN) is a backbone of many MM regimens in the frontline and relapsed settings; therefore, patients with relapsed/refractory (RR) MM are often LEN-refractory. This phase 1/2 study evaluates the combination of pomalidomide (POM), an oral immunomodulator, and ixazomib (Ix), an oral proteasome inhibitor, in patients with RRMM and high-risk cytogenetics.

Researchers sought to determine the maximum tolerated dose of Ix in combination with standard dose POM and dexamethasone (DEX) and to evaluate the antitumor activity of the triplet. The treatment regimen included 2 dose levels (3 mg and 4 mg) of Ix on days 1, 8, 15; POM 4 mg days 1-21; and DEX 40 mg days 1, 8, 15, 22, of a 28-day cycle. The study included patients with RRMM after >1 prior therapy who were LEN-refractory with grade 1 or no peripheral neuropathy (PN). Patients were treated until progression or unacceptable toxicity.

A total of 31 patients were evaluable for toxicity and response. Median age was 62 years, median time from diagnosis was 3.6 years, and patients had a median of 2 prior therapies. A total of 20 (63%) patients were double-refractory (to LEN and bortezomib) and 3 (9%) were triple-refractory to LEN, bortezomib, and carfilzomib.

Of 31 patients treated in phases 1 and 2, 45% achieved overall response (very good partial response [VGPR], n = 5; partial response, n = 9), and the clinical benefit rate was 81% (VGPR, n = 5; PR, n = 9; minimal response, n = 3; stable disease, n = 8).

Investigators concluded that the triplet regimen (Ix/POM/DEX) is a promising oral combination therapy in high-risk patients, given that more than 60% of patients were dual-refractory.

Krishnan A, et al. ASH 2016. Abstract 3316.

Related Items
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent
Last modified: May 17, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME